This inventor holds 1 USPTO granted patent. Top assignee: Acadia Pharmaceuticals Inc.. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Innovations of Allan K Uldan in Neurodegenerative Disease Therapeutics
Introduction
Allan K Uldan is a notable inventor based in Vaerloese, Denmark. He has made significant contributions to the field of pharmacology, particularly in developing therapeutics for neurodegenerative diseases. His work focuses on the role of serotonin receptors in treating conditions such as Parkinson's Disease and psychosis.
Latest Patents
Uldan holds a patent for "Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases." This patent highlights the behavioral pharmacological data associated with a novel and selective 5HT2A/2C receptor inverse agonist. The compound demonstrates in vivo efficacy in models of psychosis and dyskinesias. Notably, it shows activity in reversing MK-801 induced locomotor behaviors, suggesting its potential as an efficacious anti-psychotic. Additionally, it exhibits activity in an MPTP primate model of dyskinesias, indicating its efficacy as an anti-dyskinesia agent. These findings support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans. The compound and related agents are proposed as novel therapeutics for Parkinson's Disease and other related neurodegenerative diseases.
Career Highlights
Allan K Uldan is currently associated with Acadia Pharmaceuticals Inc., where he continues to advance his research in neuropharmacology. His innovative approach to drug development has positioned him as a key figure in the search for effective treatments for debilitating neurological conditions.
Collaborations
Uldan has collaborated with notable colleagues, including David M Weiner and Robert E Davis. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic agents.
Conclusion
Allan K Uldan's contributions to the field of neurodegenerative disease therapeutics exemplify the impact of innovative research in pharmacology. His work not only advances scientific understanding but also holds promise for improving the lives of individuals affected by these challenging conditions.